MGH and Dana‑Farber researchers built Aladynoulli, an AI trained on about 683,000 records that estimates risk for 348 conditions and could be tested inside hospital EHRs.

A Cambridge startup spun out of Toyota research revealed a $300M raise and a $1.1B valuation as it pushes humanoid machines into factory work.

Clark University won a $27M Department of Labor award to scale TechImpact, targeting 3,800 IT apprentices and employer incentive payments.

A Mayo Clinic‑led effort trained AI on thousands of patch‑test photos to read rash images; early trials show good specificity but more validation is needed.

Harvard astrophysicist Avi Loeb will chair a new UAP Science Advisory Council advising a White House UAP board; the group has requested more than 50 Pentagon records.

Vertex will buy Crinetics for about $10 billion, adding an FDA‑approved oral acromegaly drug and a late‑stage CAH candidate. The deal is expected to close in Q3 2026.

Novartis agreed to buy Myricx Bio for up to $1.5 billion, adding a novel ADC payload platform and underscoring the Boston‑area connections between small biotech and big pharma. The deal could reshape local hiring and partnership flows as programs move toward clinical development.

Alloy Therapeutics’ April Series E and spring deals with Biogen and AbbVie pushed the Waltham company toward a roughly $1B valuation and heightened investor interest.

A federal judge allowed most of a whistleblower suit accusing Harvard and a leading researcher of misusing $275M in NIH grants to proceed, keeping two False Claims Act counts alive.

Remix Therapeutics has agreed to a reverse merger with Passage Bio and lined up an oversubscribed $100M private placement to fund REM‑422 into pivotal readouts.

Thousands of Xfinity customers reported service interruptions Monday; outage trackers logged a sharp spike while engineers worked to restore service.

The FDA says ZOLL Medical’s Chelmsford facility failed to meet device quality and reporting rules. The company has fifteen business days to outline fixes or face enforcement.

Nano Dimension signed a non‑binding term sheet to merge with Infinite Epigenetics in a proposed $890M stock deal that would pivot the Waltham company into AI‑powered health diagnostics. The combined firm would seek the Nasdaq ticker IEAI and access to more than $400M in cash at closing.